Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
SOUTHAMPTON, England, June 29 /PRNewswire/ -- Vantia Therapeutics, an
emerging pharmaceutical company developing novel, small molecule drugs
targeting large, underserved medical markets, announces positive results from
a Phase IIa clinical trial of its lead development compound VA106483 for
Newly Published Article Details How PGS Techniques Directly Effect Successful Pregnancy Outcomes
Fertility and Sterility Publishes Article Underscoring Importance of PGD Technique and Method
LIVINGSTON, N.J., May 27 /PRNewswire/ -- A group of fertility experts, who pioneered the development of Preimplantation Genetic Screening (PGS), are sharing the step-by-step best practices and expla...
Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients
- Fifth International Phase III ACTEMRA Study Meets its Primary Endpoints -
NUTLEY, N.J., May 25 /PRNewswire/ -- Roche today announced that two-year data from the LITHE (Toci LI zumab Safety and THE Prevention of Structural Joint Damage) study demonstrated that ACTEMRA(R) (tocilizumab...
New Studies Show Popular Heartburn Medications Moderate the Effect of Taking Widely Prescribed Heart Drug
- Four of the most commonly used proton pump inhibitors raise risk of heart attack and stroke for patients taking Plavix(R) and increase healthcare costs
- Drug interaction increases annual hospital costs by nearly 40 percent
FRANKLIN LAKES, N.J., May 6 /PRNewswire-FirstCall/ -- Four ...
Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
SCOTTSDALE, Ariz., Feb. 10 /PRNewswire/ -- Recent clinical data show that Restylane (R) lasted 18 months in 97% of patients with one repeat injection. Restylane (R) is the only HA filler with an 18-month FDA-approved duration claim.
These data were generated in a controlled, randomiz...
New Research Reveals Unforeseen Side Effect of the Breast Cancer Movement
PHILADELPHIA and SAN ANTONIO, Texas, Dec. 12 /PRNewswire-USNewswire/ -- A
groundbreaking study developed by Breastcancer.org reports that American girls
are significantly affected by the steady stream of information and messaging
around breast cancer. This study surveyed over 2,400 girls ages 8-1...
Leading Cardiologist Joins Ontario Research Firm to Conduct New Clinical Trial on the Effect of Pantethine on Cholesterol Levels
Dr. John A. Rumberger and KGK Synergize Will Study Ingredient's
Impact on North Americans
NEW YORK, Sept. 25 /PRNewswire/ -- Daiichi Fine Chemical Co., Ltd. of
Japan today announced that it has selected world-renowned Cardiologist Dr.
John A. Rumberger and the Contract Research Division of...
Newly Released Data on Onset of Effect and Patient Perception With SYMBICORT in Adults With Asthma
WILMINGTON, Del., Sept. 10 /PRNewswire-FirstCall/ -- Newly released
results from two previously published studies demonstrated patients
receiving the maintenance combination asthma therapy SYMBICORT(R)
(budesonide/formoterol fumarate dihydrate) Inhalation Aerosol achieved
bronchodilation, or o...
Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacell's ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
SOMERSET, N.J., July 21 /PRNewswire-FirstCall/ -- Alfacell Corporation
(Nasdaq: ACEL ) today announced that a paper published in Molecular Cancer
Therapeutics (2008; 7(7):1871-9) reports that a combination of ONCONASE
(ranpirnase) and the thiazolidinedione antidiabetic drug rosiglitazone
Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies
New research continues to reinforce the efficacy of RESPeRATE while highlighting interest in the device by the scientific community
BERLIN and NEW YORK, June 16 /PRNewswire/ -- European Society of
Hypertension -- Booth # 21, Hall 15.1 -- InterCure Ltd., a medical device
company publicly t...
Bionovo's Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
- Results Presented at Endocrine Society 90th Annual Meeting -
SAN FRANCISCO and EMERYVILLE, Calif., June 16 /PRNewswire-FirstCall/ --
Bionovo Inc. (Nasdaq: BNVI ) today announced results from in vitro studies
in neurons of its drug candidate, MF101. The data were presented at the
TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
LA JOLLA, Calif., June 4 /PRNewswire-FirstCall/ -- TorreyPines
Therapeutics, Inc. (Nasdaq: TPTX ) today announced it has initiated a
clinical trial to evaluate the analgesic effect
of NGX426, the oral prodrug
of its lead product candidate, tezampanel.
The randomized, double-blind, placebo-c...
Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
- Second filing provides opportunity for additional indications and increased potential market -
PLYMOUTH MEETING, Pa., Jan. 23 /PRNewswire-FirstCall/ -- Genaera
Corporation (Nasdaq: GENR ) today announced that the investigational new
drug (IND) application submitted to...
Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy
COGENT Trials To Enroll 4,000 Patients Worldwide
MENLO PARK, Calif., Nov. 15 /PRNewswire/ -- Cogentus Pharmaceuticals,
Inc. announced today it is launching a global Phase III clinical program to
evaluate the efficacy and safety of its novel combination therapy CGT-2168.
New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure
ORLANDO, Fla., Nov. 5 /PRNewswire-FirstCall/ -- New data from the
CORONA study presented today at the American Heart Association 2007
Scientific Sessions showed that adding a statin to optimized heart failure
treatment did not significantly improve the prognosis for patients with
Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
Analysis of study showed effect
size of VYVANSE ranged from 1.39 to 1.73
BOSTON, Oct. 26 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq:
SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today
announced results from an analysis of VYVANSE(TM) (lisdexamfetamine
Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
- NEXIUM(R) (esomeprazole magnesium) Proven Effective at Standard Doses Regardless of Body Mass Index -
PHILADELPHIA, Oct. 16 /PRNewswire-FirstCall/ -- The link between
gastroesophageal reflux disease (GERD) and obesity has long been
established, but healthcare professionals...
New Study Shows Concord Grape Juice has a Heart-Healthy Effect not yet Reported With Red Wine
CONCORD, Mass., Oct. 2 /PRNewswire/ -- Many studies have suggested that
moderate red wine consumption is beneficial to cardiovascular health. But
what if you'd like to skip the alcohol? Take heart: laboratory research,
just presented at the WINEHEALTH 2007 conference in Bordeaux, France,
CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
VIENNA, Va., Oct. 7 /PRNewswire-FirstCall/ -- CEL-SCI Corporation
(NYSE: CVM ) announced today that it has entered into a Material Transfer
Agreement (MTA) with the National Institutes of Health Clinical Center
(NIHCC) and the laboratory of Dr. Francesco M. Marincola, M.D., to
NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
PARIS, September 15 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext
Paris: COX) today announced successful top-line results from the second
phase 3 study for naproxcinod in 1020 patients with osteoarthritis of the
knee (the 302 study). Both doses of naproxcinod (750 mg and 375 mg bid) met
Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study
Showing Anti-Cancer Effect with Lead RNAi Candidate
PASADENA, Calif.--(BUSINESS WIRE)--Apr 3, 2007 - Arrowhead Research
Corporation (NASDAQ: ARWR) announced the publication by its
majority-owned subsidiary Calando Pharmaceuticals, Inc. of a study
demonstrating the anti-proliferative effect
of the siRNA sequence
selected as the therapeutic component ...
Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With
Seasonal Influenza Vaccine
SAN FRANCISCO, April 11, 2007 /PRNewswire-FirstCall/ -- Vical
Incorporated today announced that a seasonal influenza vaccine
formulated with the company's Vaxfectin(TM) adjuvant generated up
to 60-fold higher antibody responses than an unformulated vaccine
at the same dose in a recently completed ...
Telik Reports Positive Data Demonstrating Synergy in Combination
and Highly Statistically Significant Effect of Telcyta as
Maintenance Therapy in First-Line Non-Small Cell Lung Cancer
PALO ALTO, Calif., April 17, 2007 /PRNewswire-FirstCall/ --
Telik, Inc. announced the presentation today of results from a
Phase 2 clinical trial of the triplet combination of TELCYTA(R)
(canfosfamide HCl, TLK286), carboplatin and paclitaxel in the
first-line treatment of advanced non-small cell l...
Oncolytics Biotech Inc. Research Collaborators Demonstrate
Reovirus/Gemcitabine Combination Has Synergistic Effect Against
Human Colon Cancer Cell Lines
CALGARY, April 17, 2007 /PRNewswire-FirstCall/ - Oncolytics
Biotech Inc. ("Oncolytics") announces that a poster by Dr. Maureen
E. Lane et al. of , New York, entitled "In Vivo Synergy between
Oncolytic Reovirus and Gemcitabine in Ras-Mutated Human HCT116
Xenografts" is scheduled to be presented tod...
Viventia biotech reports synergystic effect of its Proxinium
antibody in combinaton with chemotherapy and radiation
- Results Reported at the American Association for Cancer Research
(AACR) Annual Meeting -
TORONTO, April 18, 2007 /PRNewswire/ - Viventia Biotech Inc., a
privately held biopharmaceutical company advancing a portfolio of
novel antibody products focused on cancer, today announced results
of in vitr...
Regular Yoga Practice Is Associated With Mindful Eating
...ge spread in normal-weight people and may promote weight loss in those who are overweight. At the time, the researchers suspected that the weight-loss effect
had more to do with increased body awareness, specifically a sensitivity to hunger and satiety than the physical activity of yoga practice itself.
Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
...agnesemia and diarrhea.
Originally designed to compare the treatment effect
in the overall population, the study was amended to analyze outcomes with r...ts that implicate an entire class of products could have a material adverse effect
on sales of the affected products and on our business and results of operat...
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
...from its collaboration with GSK, including the $500,000 discovery milestone payment that Regulus received from GSK for demonstrating a pharmacological effect
in immune cells by specific microRNA inhibition.
Excluding non-cash compensation expense related to stock options, operating expenses for Regul...
Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis
...inical trial was to assess safety and evaluate the effect
of three doses of BA058 on bone formation markers ...t the critical anatomic sites with less resorptive effect
and less hypercalcemia compared to PTH and its ana...peutics by stimulating bone formation with limited effect
on bone resorption and less risk of hypercalcemia....
Labopharm files New Drug Submission with Health Canada for novel antidepressant
...ts with major unipolar depressive disorder demonstrated the efficacy of Labopharm's formulation as a treatment for depression, as well as its positive effect
on quality of sleep. The primary efficacy endpoint of the study was to compare the change in the Hamilton Rating Scale for Depression (HAMD-17) total ...
Nektar Therapeutics Reports Second Quarter 2009 Financial Results
... Net cash used in financing activities $(526) $(768)
of exchange rates on cash and cash
equivalents (109) (164)
Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
...scovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect
on sales of the affected products and on our business and results of operations.
The scientific information discussed in this news release rela...
TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men
...nd to and use the insulin it produces) to increase, yet it had a beneficial effect
on lipids (molecules in the blood that include cholesterol and triglycerides).
"It's extremely unusual to analyze the effect
of both growth hormone and sex steroids," said Harman.
Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
...lignant Syndrome (NMS) is a rare, but serious side effect
that could be fatal and has been reported with INV...(TM) is that it may change your heart rhythm. This effect
is potentially serious. You should talk to your do...s a rare, but serious and sometimes permanent side effect
reported with INVEGA((R)) SUSTENNA(TM) and similar...
Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk
...n with tamoxifen.
Antidepressants are often prescribed when women receiving tamoxifen are depressed, or to treat hot flashes -- a common side effect
of the breast cancer drug. Paxil, Prozac and Zoloft are among a group of antidepressant drugs known as CYP2D6 inhibitors. These drugs prevent the CYP...
Pennsylvania Agriculture Department Issues Quarantine for Allegheny County Horse Stable
... stable and contain the virus."
The quarantine covers the entire property, including five barns housing more than 100 horses. It will remain in effect
until a period of 21 days has elapsed without relevant clinical signs in any horses. At that point, all horses will be tested for EHV-1 and the quaran...
Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis
The data also showed that dirucotide was generally well tolerated. There were no unexpected safety or tolerability issues. The most common side effect
reported was injection site reaction. More details of the MAESTRO-01 study results are expected to be presented at a medical conference later this yea...
Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms
2. Bazedoxifene/Conjugated Estrogens (BZA/CE): Incidence of Uterine Bleeding in Postmenopausal Women (Archer DF, et al)
To evaluate the effect
of treatment with BZA/CE on uterine bleeding, trial participants were asked to record in a diary whether or not they experienced bleeding and/or spott...
Cryo-Cell Announces C'elle(SM) Research and Development Collaboration with Cryopraxis Cryobiology Ltd.
...er than C'elle can be commercialized, and the Company's development of its final business and economic model in offering any such service; any adverse effect
or limitations caused by recent increases in government regulation of stem cell storage facilities; any increased competition in our business; any dec...
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
...roup versus the placebo group in the Synovitis and Osteitis scores, while the Erosion scores, known to be the slowest to change, showed no significant effect
at three months. The most frequent adverse events were as expected from the earlier TASKi trials and appear to be manageable.
Rigel will host...